| Outcome Measures: |
Primary: Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24, HbA1c analysis will be performed on a blood sample obtained by study personnel., Baseline, Week 24 | Secondary: Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12, HbA1c analysis will be performed on a blood sample obtained by study personnel., Baseline, week 12|Mean Change From Baseline in Fasting Plasma Glucose(FPG) at Week 12 and 24, FPG analysis will be performed on a blood sample obtained by study personnel., Baseline, week 12, week 24|Mean Change From Baseline in Postprandial Plasma Glucose(PPG) at Week 12 and 24, PPG analysis will be performed on a blood sample obtained by study personnel., Baseline, week, week 24|Mean Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) Detected by Continuous Glucose Monitoring System (CGMS) After 24-week, Mean amplitude of glycemic excursions (MAGE), which was used to quantify major swings of glycaemia and assess intra-day glycemic variability, was measured by inserting continuous glucose monitoring system (CGMS) in patients for 72 consecutive hours before Day 1 (Visit 2) and Week 24 (Visit 5). In order to unify the different initial time and time of completion in each patient, only the data recorded from Day 2 00:00 to Day 3 23:59 with total 48 hours were analyzed., Baseline, week 24|The Percentage of Patients Achieving the Two Glycemic Goals After 12- and 24-week Treatment, Patients reaching glycemic goal of HbA1c ≤ 6.5% and ≤ 7.0% at week 12 and 24 will be calculated respectively., week 12, week 24
|
